Clinical trials: Nephropathy, Diabetic
CKD, Diabetic Kidney Disease
Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy
This randomized study evaluates the effect of subcutaneous semaglutide /in combination with lifestyle counseling in patients with type 2 diabetes mellitus (T2DM), overweight/obesity, and stage 4-5 chronic kidney disease (CKD) or…
- Conditions
- CKD, Diabetic Kidney Disease, Type 2 Diabetes Mellitus in Obese, Obesity
- Trial name
- RAISE-KT (NCT04741074)
- Testing
- Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Geisinger Clinic
Kidney Diseases, Diabetic Nephropathies
First-In-Human Study of GFB-024 in Healthy Overweight and Obese Participants, and Participants With Type 2 Diabetes
GFB-024 is intended for use in patients with kidney disease such as diabetic nephropathy. This study is the first time GFB-024 has been used in humans.
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Diabetes Complications, Diabetes Mellitus
- Trial name
- NCT04880291
- Testing
- GFB-024
- Where
- United States
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Goldfinch Bio, Inc.
Microalbuminuria
Low Dose Versus Aggressive Inhibition of the Renin-Angiotensin-Aldosterone (RAS) to Treat Microalbuminuria
The objective of the study is to assess the effect of standard versus aggressive inhibition of the renin-angiotensin system (RAS)in type 2 diabetic patients with microalbuminuria (MA) on; a)progression of microalbuminuria…
- Trial name
- END-IT (NCT00907374)
- Testing
- benazepril
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Charles Drew University of Medicine and Science
Type 2 Diabetes With Renal Manifestations
Clinical Study of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Type 2 Diabetic Nephropathy
The study was a 48-week multicenter, randomized, double-blind, placebo-controlled trial that included 8 weeks of pre-screening and lifestyle education, 32 weeks of treatment, and 16 weeks of follow-up.To observe the efficacy and…
- Trial name
- NCT04216849
- Testing
- human umbilical cord mesenchymal stem cells, saline
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Shanghai East Hospital
Kidney Diseases
China Kidney Patient Trials Network
This is a prospective multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease in China.
- Trial name
- CKPTN (NCT05036850)
- Where
- China
- Volunteers
- 1,200 people
- Sponsor
- George (Beijing) Clinical Research Co. Ltd.
Diabetes Mellitus, Type 1, Diabetic Nephropathy
Study of Alagebrium in Patients With Insulin-Dependent Type 1 Diabetes and Microalbuminuria
Based upon the preclinical evidence in models of diabetic nephropathy under conditions approximating both type I and II diabetes, treatment with alagebrium appears to have favorable and advantageous effects on the biochemical…
- Trial name
- NCT00557518
- Testing
- Alagebrium
- Where
- 6 sites in Australia, Denmark
- Volunteers
- 80 people
- Sponsor
- Synvista Therapeutics, Inc
Kidney Failure, Chronic, Diabetic Nephropathies
Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant.
This is a 12-month, phase II, prospective, open label study, to evaluate the effect of mycophenolate mofetil (MMF) among patients on the kidney transplant list with high Panel of Reactive Antibody (PRA) levels.
- Conditions
- Kidney Failure, Chronic, Diabetic Nephropathies, Glomerulonephritis, IGA, Hypertension, Renal
- Trial name
- NCT00446459
- Testing
- mycophenolate mofetil (CellCept)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Washington
Diabetic Nephropathy
Safety, Tolerability and Efficacy of Nidufexor in Patients With Diabetic Nephropathy
Nidufexor addresses fibrosis, oxidative stress, inflammation and cell death, and therefore has the potential to improve the management of diabetic kidney disease when added to the standard of care (SoC) (angiotensin converting…
- Trial name
- NCT03804879
- Testing
- Nidufexor, Standard of Care (SoC)
- Where
- 18 sites in United States, Argentina and 5 more
- Volunteers
- 83 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Nephropathies
Low Energy Shockwave Therapy (LE-SWT): A Novel Treatment for Chronic Kidney Disease
The investigators aim to investigate whether low energy shockwave therapy (LE-SWT) can preserve kidney function in diabetic patients. Participants in this study will receive LE-SWT treatment 6 times over 3 weeks.
- Trial name
- NCT02515461
- Testing
- Low energy shockwave therapy
- Where
- Denmark
- Volunteers
- 30 people
- Sponsor
- Odense University Hospital
Kidney Diseases
Global Kidney Patient Trials Network
This is a prospective international multi-centre, observational cohort study of incident and prevalent patients diagnosed with a kidney disease
- Trial name
- GKPTN (NCT04389827)
- Where
- Australia
- Volunteers
- 5,999 people
- Sponsor
- The George Institute
Type 1 Diabetes Mellitus With Diabetic Nephropathy
Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children
About 30 to 40% of patients suffering from type I diabetes are at risk of developing a diabetic nephropathy (DN) leading more or less rapidly to an end-stage renal disease.
- Trial name
- peeDIAB2 (NCT02164279)
- Testing
- Urinary sample collection
- Where
- 2 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Toulouse
Diabetic Nephropathy, Diabetes Mellitus
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
The Family Investigation of Nephropathy and Diabetes (FIND) is a multicenter study designed to identify genetic determinants of diabetic kidney disease.
- Conditions
- Diabetic Nephropathy, Diabetes Mellitus, Diabetic Kidney Disease, Albuminuria
- Trial name
- NCT00342927
- Where
- United States
- Volunteers
- 9,084 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetic Nephropathy
Assessment of the Effect of Captopril Versus Combination of Captopril and Pentoxifylline on Reducing Proteinuria in Type 2 Diabetic Nephropathy
Diabetic nephropathy is the most common cause of ESRD and has a great impact on mortality and morbidity of diabetic patients. Despite renoprotective effect of ACE inhibitors in diabetic patients they can not hinder the…
- Trial name
- NCT00663949
- Testing
- Captopril, Captopril + Pentoxifylline
- Where
- Iran
- Volunteers
- 70 people
- Sponsor
- Shiraz University of Medical Sciences
Diabetic Kidney Disease
Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD
1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease. 2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on…
- Trial name
- NCT06069076
- Testing
- cathepsin S and chromogranin A
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Assiut University
Type 1 Diabetes Mellitus With Diabetic Nephropathy
dApagliflozin SC0062 and Prevention of Renal Injury; a Randomized Evaluation
The aim of this study is to test the hypothesis that dapagliflozin (SGLT2 inhibitor) and SC0062 (ERA) combination therapy augments nephroprotection and mitigates fluid retention and ketogenesis in people with T1D through…
- Trial name
- ASPIRE-1 (NCT06072326)
- Testing
- Dapagliflozin (Forxiga®), SC0062 strength 10mg, SC0062 and dapagliflozin
- Where
- 5 sites in Denmark, Finland
- Volunteers
- 36 people
- Sponsor
- University Medical Center Groningen
Diabetes Type 2, Kidney Disease
Digital Support for Reducing Salt Intake Among Patients With Diabetic Kidney Disease: Protocol for a Controlled Clinical Trial
This study evaluates whether a digital patient education program can improve adherence to KDIGO 2022 dietary recommendations (low sodium and optimal protein intake) among patients with type 2 diabetes and chronic kidney disease…
- Trial name
- StenoFOODApp (NCT07485075)
- Testing
- StenoFood App
- Where
- 2 sites in Denmark
- Volunteers
- 104 people
- Sponsor
- Steno Diabetes Center Copenhagen
Sepsis, Acute Renal Failure
Inferior Vena Cava Collapsibility and Distensibility Assessment in Critical Care.
This study will help in determining the impact of assessment of Inferior Vena Cava Collapsibility and Distensibility Index (IVC CI and DI) through Point Of Care Ultra Sound (POCUS), for the fluid management of critically ill…
- Conditions
- Sepsis, Acute Renal Failure, Acute Gastroenteritis, Diabetic Ketoacidosis
- Trial name
- NCT06516692
- Testing
- Inferior Vena Cava Collapsibility/distensibility Index (IVC CI/DI) assessment
- Where
- Pakistan
- Volunteers
- 180 people
- Sponsor
- Jinnah Postgraduate Medical Centre
Diabetic Kidney Disease, Diabetes Mellitus, Type 2
EMPRA (EMPagliflozin and RAs in Kidney Disease)
This study will be a prospective, clinical pilot study in CKD patients to show whether Empagliflozin in addition to ACEi treatment significantly increases Ang 1-7 levels compared to ACEi treatment alone.
- Conditions
- Diabetic Kidney Disease, Diabetes Mellitus, Type 2, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4
- Trial name
- EMPRA (NCT03078101)
- Testing
- Empagliflozin 10 MG [Jardiance]
- Where
- Austria
- Volunteers
- 51 people
- Sponsor
- Medical University of Vienna
Diabetic Nephropathies, Hypertension
Efficacy and Safety of Telmisartan Compared With Losartan
A study to evaluate the efficacy and safety of telmisartan compared with losartan in patients with diabetic nephropathy and hypertension
- Trial name
- NCT06431477
- Testing
- telmisartan, Losartan
- Where
- South Korea
- Volunteers
- 98 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Nephropathy, Diabetic Nephropathies
Prevention of Chronic Kidney Disease(CDK) Progression in Type 1 Diabetes With Long Term Use of Sodium-Glucose-coTransporter Inhibitors Avoiding Kidney hypOxia
Background: Sodium-glucose-cotransporter (SGLT) inhibition has been observed to reduce risk of cardiovascular events and kidney failure in persons with type 2 diabetes.
- Conditions
- Nephropathy, Diabetic Nephropathies, Diabetes Mellitus, Type 1, Albuminuria
- Trial name
- PLUTO (NCT06147232)
- Testing
- Sotagliflozin
- Where
- 2 sites in Denmark, United Kingdom
- Volunteers
- 69 people
- Sponsor
- Steno Diabetes Center Copenhagen